Guggenheim began coverage on shares of Passage Bio (NASDAQ:ORIC) in a research report sent to investors on Tuesday, BenzingaRatingsTable reports. The firm issued a buy rating and a $45.00 price target on the stock.
ORIC stock opened at $29.04 on Tuesday. Passage Bio has a twelve month low of $24.26 and a twelve month high of $34.70.
Passage Bio (NASDAQ:ORIC) last released its earnings results on Wednesday, May 20th. The company reported ($4.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($4.20). Equities analysts anticipate that Passage Bio will post -1.77 earnings per share for the current fiscal year.
Passage Bio Company Profile
ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors.
See Also: Are FAANG stocks a good investment?
Receive News & Ratings for Passage Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Passage Bio and related companies with MarketBeat.com's FREE daily email newsletter.